• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Kiora Pharmaceuticals Inc.

    4/21/26 4:46:43 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KPRX alert in real time by email
    Form D
    FORM D
    Notice of Exempt Offering of Securities

    UNITED STATES SECURITIES
    AND EXCHANGE COMMISSION
    Washington, D.C.

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated Average burden hours per response: 4.0
    1. Issuer's Identity
    CIK (Filer ID Number)Previous Name(s)Checkbox not checkedNoneEntity Type
    0001372514
    EYEGATE PHARMACEUTICALS INC
    Radio button checkedCorporation
    Radio button not checked Limited Partnership
    Radio button not checked Limited Liability Company
    Radio button not checked General Partnership
    Radio button not checked Business Trust
    Radio button not checkedOther 
    Name of Issuer
     KIORA PHARMACEUTICALS INC
    Jurisdiction of Incorporation/Organization
    DELAWARE 
    Year of Incorporation/Organization
    Radio button checkedOver Five Years Ago
    Radio button not checkedWithin Last Five Years (Specify Year)
     
    Radio button not checkedYet to Be Formed
     
      
      
     
    2. Principal Place of Business and Contact Information
    Name of Issuer
     KIORA PHARMACEUTICALS INC
    Street Address 1Street Address 2
     169 SAXONY RD.
     SUITE 212
    CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
     ENCINITAS
     CALIFORNIA
     
     92024
     858-224-9600 




    3. Related Persons

    Last NameFirst NameMiddle Name
    Strem
    Brian
    Street Address 1Street Address 2
     169 Saxony Rd. Suite 212 
     
    CityState/Province/CountryZIP/Postal Code
     Encinitas
     CALIFORNIA
     92024
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    President and Chief Executive Officer



    Last NameFirst NameMiddle Name
    Tosca
    Melissa
    Street Address 1Street Address 2
     169 Saxony Rd. Suite 212 
     
    CityState/Province/CountryZIP/Postal Code
     Encinitas
     CALIFORNIA
     92024
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Chief Financial Officer



    Last NameFirst NameMiddle Name
    Stengone
    Carmine
    Street Address 1Street Address 2
     169 Saxony Rd. Suite 212 
     
    CityState/Province/CountryZIP/Postal Code
     Encinitas
     CALIFORNIA
     92024
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Shapiro
    Aron
    Street Address 1Street Address 2
     169 Saxony Rd. Suite 212 
     
    CityState/Province/CountryZIP/Postal Code
     Encinitas
     CALIFORNIA
     92024
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Walters-Hoffert
    Lisa
    Street Address 1Street Address 2
     169 Saxony Rd. Suite 212 
     
    CityState/Province/CountryZIP/Postal Code
     Encinitas
     CALIFORNIA
     92024
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Tyle
    Praveen
    Street Address 1Street Address 2
     169 Saxony Rd. Suite 212 
     
    CityState/Province/CountryZIP/Postal Code
     Encinitas
     CALIFORNIA
     92024
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Hollander
    David
    Street Address 1Street Address 2
     169 Saxony Rd. Suite 212 
     
    CityState/Province/CountryZIP/Postal Code
     Encinitas
     CALIFORNIA
     92024
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Parsons
    Erin
    Street Address 1Street Address 2
     169 Saxony Rd. Suite 212 
     
    CityState/Province/CountryZIP/Postal Code
     Encinitas
     CALIFORNIA
     92024
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     





    4. Industry Group
     Radio button not checkedAgriculture
    Banking & Financial Services
     Radio button not checked Commercial Banking
     Radio button not checked Insurance
     Radio button not checkedInvesting
     Radio button not checked Investment Banking
     Radio button not checked Pooled Investment Fund

     Radio button not checkedOther Banking & Financial Services
    Radio button not checked Business Services
    Energy
     Radio button not checked Coal Mining
     Radio button not checked Electric Utilities
     Radio button not checked Energy Conservation
     Radio button not checked Environmental Services
     Radio button not checked Oil & Gas
     Radio button not checked Other Energy
    Health Care
     Radio button not checked Biotechnology
     Radio button not checked Health Insurance
     Radio button not checked Hospitals & Physicians
     Radio button checked Pharmaceuticals
     Radio button not checked Other Health Care
       
       
       
      
    Radio button not checked Manufacturing
    Real Estate
     Radio button not checkedCommercial
     Radio button not checkedConstruction
     Radio button not checkedREITS & Finance
     Radio button not checkedResidential
    Radio button not checkedOther Real Estate
    Radio button not checked Retailing
    Radio button not checkedRestaurants
    Technology
    Radio button not checked Computers
    Radio button not checked Telecommunications
    Radio button not checked Other Technology
    Travel
    Radio button not checked Airlines & Airports
    Radio button not checked Lodging & Conventions
    Radio button not checked Tourism & Travel Services
    Radio button not checked Other Travel
    Radio button not checkedOther

      
       
    5. Issuer Size
    Revenue RangeAggregate Net Asset Value Range
    Radio button not checkedNo RevenuesRadio button not checked No Aggregate Net Asset Value
    Radio button not checked $1 - $1,000,000Radio button not checked$1 - $5,000,000
    Radio button not checked $1,000,001 - $5,000,000Radio button not checked $5,000,001 - $25,000,000
    Radio button not checked$5,000,001 - $25,000,000Radio button not checked $25,000,001 - $50,000,000
    Radio button not checked$25,000,001 - $100,000,000Radio button not checked $50,000,001 - $100,000,000
    Radio button not checked Over $100,000,000Radio button not checked Over $100,000,000
    Radio button checked Decline to Disclose Radio button not checkedDecline to Disclose
    Radio button not checked Not ApplicableRadio button not checked Not Applicable

     
    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
    Checkbox not checkedRule 504(b)(1) (not (i), (ii)
    or (iii))
    Checkbox checkedRule 506(b)      
    Checkbox not checkedRule 504 (b)(1)(i) Checkbox not checkedRule 506(c)
    Checkbox not checkedRule 504 (b)(1)(ii) Checkbox not checkedSecurities Act Section 4(a)(5)
    Checkbox not checkedRule 504 (b)(1)(iii)Checkbox not checkedInvestment Company Act Section 3(c)
     
     

    7. Type of Filing
    Checkbox checked New Notice Date of First Sale 
    2026-04-06
    Checkbox not checked First Sale Yet to Occur
    Checkbox not checked Amendment


     
     
    8. Duration of Offering
    Does the Issuer intend this offering to last more than one year? Radio button not checked Yes Radio button checked No
     
     
    9. Type(s) of Securities Offered (select all that apply)
    Checkbox not checkedPooled Investment Fund InterestsCheckbox checkedEquity
    Checkbox not checkedTenant-in-Common Securities Checkbox not checkedDebt
    Checkbox not checkedMineral Property SecuritiesCheckbox checkedOption, Warrant or Other Right to Acquire Another Security
    Checkbox checkedSecurity to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire SecurityCheckbox not checkedOther (describe)
     
     
     
    10. Business Combination Transaction
    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Radio button not checked Yes Radio button checked No
    Clarification of Response (if Necessary)
     
     
     
    11. Minimum Investment
    Minimum investment accepted from any outside investor$
     0
    USD

    12. Sales Compensation
    Recipient Recipient CRD NumberCheckbox not checkedNone
     
     
    (Associated) Broker or DealerCheckbox not checkedNone(Associated) Broker or Dealer CRD Number  Checkbox not checkedNone
     
     
    Street Address 1Street Address 2
     
     
    City State/Province/CountryZIP/Postal Code
     
     
     
    State(s) of Solicitation Checkbox not checkedAll States
     



    13. Offering and Sales Amounts
     
    Total Offering Amount $
    5000000
    USDCheckbox not checkedIndefinite
    Total Amount Sold $
    5000000
    USD
    Total Remaining to be Sold $
    0
    USDCheckbox not checkedIndefinite
    Clarification of Response (if Necessary)
    The common stock and warrants sold for a combined purchase price of $2.5429. Amount excludes any proceeds from a cash exercise of warrants.
     
    14. Investors

    Checkbox not checkedSelect if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
    Number of such non-accredited investors who already have invested in the offering
       
      Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    3
     
    15. Sales Commissions & Finders’ Fees Expenses
    Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
    Sales Commissions$
    0
    USDCheckbox not checkedEstimate
    Finders' Fees$
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     
     

    16. Use of Proceeds
    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
     $ 
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
    Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees to those listed in Item 3.

    Signature and Submission
     
    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
    Terms of Submission 
     In submitting this notice, each Issuer named above is: 
     
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).
     
    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.
    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.
     
    IssuerSignatureName of SignerTitleDate
    KIORA PHARMACEUTICALS INC/s/ Melissa ToscaMelissa ToscaCFO2026-04-21




    Get the next $KPRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KPRX

    DatePrice TargetRatingAnalyst
    1/19/2022$2.50Buy
    Maxim Group
    More analyst ratings

    $KPRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders

    ENCINITAS, Calif. and WASHINGTON D.C., Oct. 30, 2025 /PRNewswire/ -- Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) and Global Genes today announced that Kiora has joined Global Genes' RARE-X Vision Consortium, a corporate-nonprofit partnership with a mission to promote and facilitate collaboration among advocacy, research, and industry stakeholders to advance research leading to vision-improving therapies. The Vision Consortium aims to transform the lives of people affected by rare ocular disorders by identifying clinical trial ready populations, ensuring meaningful outcome measures, and accelerating the development of clinical trial programs required to bring new treatments to patients.

    10/30/25 9:00:00 AM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vicarious Surgical Announces Leadership Transition: Stephen From, Healthcare Industry Veteran, Appointed Chief Executive Officer

    Adam Sachs, Co-Founder, to Remain on as President Vicarious Surgical Inc. (NYSE:RBOT, RBOT WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Stephen From as Chief Executive Officer and a member of the Company's Board of Directors (the "Board"), effective August 7, 2025. Adam Sachs, current Chief Executive Officer, Co-Founder, and a member of the Board, will remain with the Company as President, Co-Founder, and a member of the Board in an operational capacity as a member of the Company's leadership team. Mr. From brings over 20 years of leadership in the healthcare and financial

    7/31/25 4:30:00 PM ET
    $KPRX
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201

    Amendment eliminates $4.75M in near-term milestones Kiora would have owed to SentrxSentrx gains access to Kiora's recently issued patents covering the combination of KIO-201 and antibiotics for veterinary useKiora will receive a royalty on net sales of products covered by licensed patentsEncinitas, California--(Newsfile Corp. - June 15, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) ("Kiora") and Sentrx Animal Care ("Sentrx") announced today they have amended their existing licensing agreement for patents and technology related to Kiora's KIO-201 product candidate. The amended agreement between the companies eliminates up to $4.75M in near-term financial payments by Kiora to Sentrx that w

    6/15/23 7:00:00 AM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stengone Carmine N. bought $4,600 worth of shares (1,250 units at $3.68) (SEC Form 4)

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    9/12/24 6:32:55 AM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Shapiro Aron bought $10,800 worth of shares (3,000 units at $3.60) (SEC Form 4)

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    9/11/24 7:02:13 AM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Walters-Hoffert Lisa bought $4,825 worth of shares (1,250 units at $3.86) (SEC Form 4)

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    8/20/24 1:00:12 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Kiora Pharmaceuticals with a new price target

    Maxim Group initiated coverage of Kiora Pharmaceuticals with a rating of Buy and set a new price target of $2.50

    1/19/22 8:19:46 AM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPRX
    SEC Filings

    View All

    SEC Form 424B3 filed by Kiora Pharmaceuticals Inc.

    424B3 - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

    5/28/26 5:28:25 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Kiora Pharmaceuticals Inc.

    EFFECT - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

    5/26/26 12:15:26 AM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Kiora Pharmaceuticals Inc.

    S-3 - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

    5/18/26 4:30:38 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Tosca Melissa

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    4/2/26 4:47:03 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Daniels Eric Joseph

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    4/2/26 4:46:14 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Strem Brian M.

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    4/2/26 4:45:32 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kiora Pharmaceuticals Inc.

    SC 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

    11/14/24 7:17:24 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Kiora Pharmaceuticals Inc.

    SC 13G - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

    11/14/24 4:45:23 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Kiora Pharmaceuticals Inc.

    SC 13G - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

    11/14/24 4:32:42 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPRX
    Leadership Updates

    Live Leadership Updates

    View All

    Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board

    Encinitas, California--(Newsfile Corp. - April 21, 2023) - Kiora Pharmaceuticals (NASDAQ:KPRX) has appointed Mark Pennesi, M.D., Ph.D., the Kenneth C. Swan Endowed Professor in Ophthalmology and Molecular and Medical Genetics and the Chief of the Paul H. Casey Ophthalmic Genetics Division at the Casey Eye Institute at Oregon Health & Science University, to their Scientific Advisory Board. As a member of the Scientific Advisory Board, his expertise and insights will contribute to the company's development of new treatments and therapies for patients suffering from eye diseases, including retinitis pigmentosa, a rare inherited degenerative eye disease in which Kiora is enrolling a clinical tri

    4/21/23 7:00:00 AM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance

    Salt Lake City, Utah--(Newsfile Corp. - September 13, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) ("Kiora" or the "Company") has appointed Melissa Tosca as Executive Vice President of Finance. Mrs. Tosca will join the executive management team and oversee finance, SEC reporting and accounting functions as well as play a role in the company's capital markets strategy and planning. "Melissa brings to our company more than 15 years of financial and operational experience in both clinical and commercial-stage biotech and life science companies," said Brian M. Strem, Ph.D., President and CEO of Kiora. "This experience will be invaluable to our goals of advancing our development pipeline and

    9/13/22 6:45:00 AM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board

    Salt Lake City, Utah--(Newsfile Corp. - February 1, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX), ("Kiora" or the "Company") announced today the appointment of Erin Parsons as a new independent Director of its Board of Directors (the "Board"). Separately, the Executive Chairman, Stephen From, has informed Kiora of his voluntary resignation from the Board. These changes are effective immediately. "I am pleased to welcome Erin Parsons to our Board of Directors," said Brian M. Strem, Ph.D, President and CEO of Kiora. "Erin brings extensive commercial and strategic expertise in eyecare, a critical and complementary perspective as we continue to dedicate efforts to develop therapeutics for e

    2/1/22 6:45:00 AM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care